Navigation Links
Combining NSAIDs With Chemotherapy May Improve Cancer Therapy

Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs . However, the latest studies have concluded that in most cases the adverse side effect of these drugs -- including risk of cardiovascular and kidney disease -- outweigh the potential benefit.

However, certain NSAIDs may be better suited to treating cancer, in combination with standard therapies, rather than preventing it, according to new research by scientists at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

"The real debate comes down to use of these compounds in two settings: cancer prevention, which involves long-term use of a drug, and cancer treatment involving short-term, focused use of the drug," said Douglas Trask, M.D., Ph.D., UI associate professor of otolaryngology head and neck surgery. "Published studies show that heart and kidney problems occur with long-term use, especially when used for more than one year. While there appear to be cardiorenal effects of NSAIDs even with short-term use, these risks may be minor compared to the potential benefit to treat cancer more effectively."

Two new UI studies show that the NSAID celecoxib has potent anticancer activity, which is associated with the drug's ability to disrupt the cell cycle -- the orderly, multi-step process by which cells divide.

In particular, the experiments showed that celecoxib specifically kills head and neck cancer cells in the S phase of the cell cycle, where the cell synthesizes new DNA and replicates its genetic material.

"The finding that the cell killing effect takes place in S phase is particularly exciting because one of the standard therapies for most cancers -- chemotherapy -- often has its maximal effect at that stage of the cell cycle," Trask said. "We're hopeful that our results will lead to a clinical trial where we
'"/>




Page: 1 2 3

Related medicine news :

1. Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid
2. Combining Therapies can Improve Survival for Early-stage Breast Cancer Patients
3. The Effectiveness Of NSAIDs Evaluated
4. NSAIDs In First trimester Linked To Congenital Anomalies In Babies
5. Study Explains How NSAIDs Halt Cancer Growth
6. Aspirin Or NSAIDs Will not Prevent Colorectal Cancer
7. Acupuncture May Help Chemotherapy Side Effects
8. Chemotherapy Pill Has Fewer Side Effects Than IV
9. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
10. Therapy Boosts Chemotherapy Effects
11. Chemotherapy Effective for Bladder Cancer
Post Your Comments:
(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3
...ined that the deadly Human Immune Deficiency Virus...accine used in Africa in the 1950s and say rumours...ce to back them up. The studies, from researchers ...d help free the polio vaccine manufactured by the ...
... most painful and bothering one is the trauma of g... according to many diabetics is the finger stick. ...p to six times a day for more than ten to twenty y...he pain and discomfort associated with them. But r...
...hursday that plans are afoot to consider listing o...n the US bourses after 2002," Pratap C Reddy, chai... was a part of the business plan for the post-2002...available at the moment, Dr. Reddy added that plan...
... can be prevented if the patients and their doctor...ng to WHO, around 150 million people suffer from a...o the disease every year. Asthma is a chronic resp...t is characterized by sudden recurring attacks of ...
Other Medicine News:
(Date:7/24/2008)...-FirstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasda...ts second Phase 3 clinical trial with AZ-004 (Stac... candidate being developed for the treatment,of ac...polar disorder.,Alexza believes the novel, non-inv...ties resulting from inhaled loxapine administratio...
(Date:7/24/2008).../ -- Headlines claiming "soy,products lower sperm ...e,preliminary study that Dr. Jorge Chavarro, publ...collected intake of soyfoods and not on,specific d...d by many,issues, thus I feel the results should b... Tammy Hedlund, a researcher in prostate cancer,pr...
(Date:7/24/2008)... body temperature, for home,and clinical use, WES...-Med, Inc.,(subsidiary of American Scientific Reso...ibutor of the Thermofocus(R) 5-in-1 non-contact,th... clinical study,conducted by the Second Children,s...y, which proves that the Thermofocus(R) measures b...
(Date:7/24/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...week,open label safety extension that was conducte...y for naproxcinod. The results revealed no unexpec...r the one-year duration of,the study, as measured ...ion, the results showed that the patients, mean bl...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Armed beetles find a mate whatever their size 2646 1Small Business Health Care Survey Points to Need for Reform 15325 1Small Business Health Care Survey Points to Need for Reform 15325 2Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 1Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 2Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 1Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 2
...PRNewswire/ -- Asenapine -- an,investigational dru... business unit of Akzo Nobel, for bipolar I disord...e effective than placebo,in treating acute manic a...er, according to new Phase III results, from a stu...on,s 2007 Annual,Meeting. , In the three-week stud...
...ent Reduction in Risk of Hospitalization,from Croh...Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbot... of a pivotal study,presented at the Digestive Dis...ng patients with moderate to severely active,Crohn...ntenance,therapy were almost 60 percent less likel...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: